Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM

Colorectal Cancer Clinical Trial

Official title:

Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX in Patients With Initially Unresectable Colorectal Liver Metastasis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03493048
• Other study ID #: ERBIRINOX-CRCLM
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: April 15, 2018
• Est. completion date: June 2025

Study information

• Verified date: April 2024
• Source: Sun Yat-sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer Liver Metastasis of RAS wildtype. The patients will be treated in two therapy groups: Experimental arm A: Chemotherapy with FOLFOXIRI + Cetuximab Standard arm B: Chemotherapy with FOLFOX + Cetuximab

Description:

We intend to carry out a randomized controlled clinical study of cetuximab plus FOLFOXIRI regimen versus cetuximab plus FOLFOX regimen in the first-line treatment of patients with initially unresectable CRLM, to answer the question of whether cetuximab plus FOLFOXIRI regimen can improve the overall ORR, surgical resection rate and OS compared with cetuximab plus FOLFOX regimen in patients with previously untreated, initially unresectable CRLM patients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 146
• Est. completion date: June 2025
• Est. primary completion date: December 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion criteria

1. Age = 18 years and = 70 years.

2. Histologically confirmed colorectal adenocarcinoma.

3. Liver metastasis confirmed by imaging or pathology.

4. The multidisciplinary team (MDT) determines that the liver metastases are unresectable, which is specifically defined as ? metastatic lesions = 5; ? ineligible for R0 resection; ? expected insufficient residual liver volume after resection; ? unable to preserve all three hepatic veins after resection, unable to ensure that the blood flow and bile ducts of the residual liver into and out of the liver could be preserved, and unable to preserve the adjacent two liver segments. Patients who meet any of the above criteria can be determined as having initially unresectable liver metastases.

5. Patients with wild-type RAS.

6. No prior treatment for liver metastases, including chemotherapy, surgery, radiotherapy, transcatheter arterial chemoembolization (TACE), and targeted therapy.

7. Absence of extrahepatic metastasis confirmed by CT, MRI or PET/CT (if necessary) (enrollment can be considered if there is a lung or lymph node lesion less than 10 mm, which is difficult to determine metastases).

8. Normal hematologic function (platelets > 90 × 109/L; leukocytes > 3 × 109/L; neutrophils > 1.5 × 109/L).

9. Serum bilirubin = 1.5 times the upper limit of normal (ULN) and transaminases = 5 times ULN.

10. No ascites, normal coagulation function, albumin = 35 g/L.

11. Liver function: Child-Push score: Class A

12. Serum creatinine < ULN, or calculated creatinine clearance > 50 ml/min (using the Cockcroft-Gault formula).

13. ECOG score 0-1.

14. Life expectancy > 3 months.

15. Sign written informed consent.

16. Willing and able to be followed up until death or end of study or study termination.

Exclusion criteria:

1. Presence of any extrahepatic metastasis and/or primary tumor that cannot be resected with radical surgery.

2. Serious arterial embolism or ascites.

3. Have bleeding tendency or coagulation disorder.

4. Have hypertensive risk or hypertensive encephalopathy.

5. Serious uncontrolled systemic complications such as infection or diabetes.

6. Clinically significant cardiovascular disease such as cerebrovascular accident (within 6 months prior to enrollment), myocardial infarction (within 6 months prior to enrollment), uncontrolled hypertension despite appropriate medical treatment. Unstable angina, congestive heart failure (NYHA class 2-4), cardiac arrhythmia requiring medication.

7. History or physical evidence of central nervous system disease (e.g., primary brain tumor, epilepsy uncontrolled by standard of care, any history of brain metastases or stroke).

8. History of other malignancies (except basal cell carcinoma of the skin and/or carcinoma in situ of the cervix after radical surgery) within the past 5 years.

9. Treatment with any ongoing investigational drug within the last 28 days prior to the study.

10. Any residual toxicity from prior chemotherapy (except alopecia), such as peripheral neuropathy = NCI CTC v4.03 Grade 2, will not be considered for oxaliplatin-containing regimen.

11. Hypersensitivity to any drug in the study.

12. Pregnant and lactating women.

13. Women of childbearing age (< 2 years after menstruation) or men of childbearing potential who are not using or refuse to use effective non-hormonal contraception (intrauterine contraceptive ring, barrier contraceptives combined with spermicidal gel, or surgical sterilization).

14. Unable or unwilling to comply with the study protocol.

15. Patients with any other diseases, dysfunction caused by metastatic lesions, or suspected disease found by physical examination, indicating possible contraindications to the use of the investigational drug or putting the patients at high risk of treatment-related complications.

Related Conditions & MeSH terms

• Colorectal Cancer
• Liver Metastases
• Neoplasm Metastasis

Intervention

Drug:
• Irinotecan
Irinotecan 130 mg/m²
• Cetuximab
Cetuximab, iv, 500mg/m2
• 5-fluorouracil
5-FU 2400 mg/m² cont. inf.
• Oxaliplatin
oxaliplatin 85 mg/m²
• Leucovorin
leucovorin 200 mg/m²

Locations

Country	Name	City	State
China	Sun Yat-sen University Cancer Center	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate	Partial response (PR) plus complete response (CR)): assessed by the investigator using RECIST v1.1 criteria	assessed up to 12 months
Secondary	Depth of Response	The investigator assesses DpR by measuring the ratio of maximum tumor regression to baseline tumor, and calculates the median value	Each follow up visit, assessed up to 12 months
Secondary	R0 Resection Rate	Defined as the proportion of patients who achieve complete resection after treatment with cetuximab plus FOLFOXIRI regimen or cetuximab plus FOLFOX regimen according to the study protocol	Each follow up visit, assessed up to 12 months
Secondary	Early Tumor Shrinkage	Target lesion reduction of a least 20% from the nadir following 4 treatment courses assessed using the RECIST version 1.1 criteria	Each follow up visit, assessed up to 12 months
Secondary	Progression-Free Survival	Assessed by the investigator using RECIST v1.1, defined as the time from the start of study treatment to disease progression, or relapse after resection of liver metastases, or death due to any cause.	Each follow up visit, assessed up to 60 months
Secondary	Overall Survival	Defined as the time from the start of study treatment to death due to any cause	Each follow up visit, assessed up to 60 months